| Vol. 8.39 – 6 October, 2020 |
| |
|
|
| Researchers found that T lymphocytes accumulated depolarized mitochondria as a result of decreased mitophagy activity and displayed functional, transcriptomic and epigenetic characteristics of terminally exhausted T cells. [Nature Immunology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators conducted a first-in-human trial of bispecific anti-CD20, anti-CD19 CAR T cells for relapsed, refractory B cell malignancies. [Nature Medicine] |
|
|
|
| Researchers report the structural basis for substrate recognition by melanoma antigen (MAGE) ubiquitin ligases. Biochemical analysis of the degron motif recognized by MAGE-A11 and the crystal structure of MAGE-A11 bound to the PCF11 substrate uncovered a conserved substrate binding cleft in MAGEs. [Nature Communications] |
|
|
|
| Scientists showed that STAT5 was the earliest factor binding and remodeling the Il9 locus to allow BATF binding in both mouse and human Th9 cultures. [Nature Communications] |
|
|
|
| The authors describe the development and use of an ad hoc protein microarray to study the immune response induced by the three major 4CMenB antigenic components in individual sera from vaccinated infants, adolescents and adults. [Nature Communications] |
|
|
|
| Researchers identified the transcription factor C/EBPβ as a key regulator for dendritic cell maturation and immunogenic functionality under homeostatic and lymphoma-transformed conditions. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists found that autocrine stimulation of the purinergic receptor P2Y11 regulated the migration of human CD4 T cells. P2Y11 receptors redistributed from the front to the back of polarized cells where they triggered intracellular cAMP/PKA signals that attenuated mitochondrial metabolism at the back. [Science Signaling] |
|
|
|
| Researchers used T-cell receptor β chain (sequencing to study the T-cell repertoire in the coronary artery, endomyocardium, and peripheral blood at the time of retransplant in four cases of cardiac allograft vasculopathy and compared it to the immunoglobulin heavy chain repertoire from the same samples. [American Journal of Transplantation] |
|
|
|
| The authors report BAFF engagement to BAFF receptor elicited both priming and activating signals for NLRP3 inflammasomes in primary B cells and B lymphoma cell lines. [Cell Death & Disease] |
|
|
|
| Investigators demonstrated that the ligation of CD300e in monocytes hampered the expression of the human leukocyte antigen class II, affecting its synthesis. [Scientific Reports] |
|
|
|
|
| Future clinical research needs to focus on the therapeutic use of androgens and progestins or their downstream signaling cascades and on new oestrogenic compounds such as tissue-selective oestrogen complex to modulate altered immune responses. [Nature Reviews Rheumatology] |
|
|
|
| The authors review the current information on the mode of action of the lineage-defining transcription factors Bcl6 and T-bet and how they act individually and in complex to govern CD4+ T-cell ontogeny. [Cellular & Molecular Immunology] |
|
|
|
| Investigators summarize evidence that apoptosis and efferocytosis are exploited in cancer, as well as discuss current translation and clinical efforts to harness signals from dying cells into therapeutic strategies. [Cells] |
|
|
|
|
| Oncocyte Corporation announced that it has agreed to enter a licensing and collaboration agreement with Chronix Biomedical. Oncocyte is licensing Chronix’s patented CNI Monitor technology for the TheraSure™-CNI MONITOR clinical assay. [Oncocyte Corporation] |
|
|
|
| Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced that their investigational new drug application for TNB-486, a bispecific T-cell engaging antibody for the treatment of B-Cell Non-Hodgkin’s lymphoma was cleared for the initiation of Phase I clinical studies by the FDA on September 30, 2020. [Teneobio, Inc.] |
|
|
|
|
| November 18, 2020 Virtual |
|
|
|
|
|
| Houston Methodist Research Institute – Houston, Texas, United States |
|
|
|
| Terasaki Research Institute – Los Angeles, California, United States |
|
|
|
| Princess Margaret Cancer Center – Toronto, Ontario, Canada |
|
|
|
| University of California, Davis – Sacramento, California, United States |
|
|
|
| Stockholm University – Stockholm, Sweden |
|
|
|
|